Suppr超能文献

链激酶与尿激酶胸膜内纤维蛋白溶解术治疗局限性胸腔积液的安全性和有效性比较研究

A Comparative Study of the Safety and Efficacy of Intrapleural Fibrinolysis With Streptokinase and Urokinase in the Management of Loculated Pleural Effusions.

作者信息

Saxena Khushboo, Maturu V Nagarjuna

机构信息

Respiratory Medicine, Gandhi Medical College, Bhopal, IND.

Department of Interventional and Clinical Pulmonary Medicine, Yashoda superspeciality Hospital, Hyderabad, IND.

出版信息

Cureus. 2022 Jun 24;14(6):e26271. doi: 10.7759/cureus.26271. eCollection 2022 Jun.

Abstract

Background Intrapleural fibrinolytic therapy (IPFT) with streptokinase (STK), urokinase (UK), and alteplase remains a common practice for managing loculated pleural effusions (LPEs). However, very limited data are available on the comparative efficacy of these agents. Methodology We compared the efficacy and safety of intrapleural streptokinase (n = 28) and urokinase (n = 38) in 66 patients with loculated effusions. IPFT was initiated if effusion remained undrained despite the placement of intercostal chest drainage or pigtail catheter. The dose of STK and UK were 250,000 IU twice daily and 100,000 IU once daily, respectively. The volume of fluid drained after IPFT, radiologic response, clinical response, and adverse events were compared between the two groups. Results The mean volume of fluid drained post-IPFT was 1,379 mL in the STK arm and 1,110 mL in the UK arm (p = 0.251). Of the 66 patients, 53 (80.3%) had good clinical response, and 28 (43.7%) had >75% resolution of effusion on chest radiographs. The clinical (79% vs. 82%; p = 0.765) and radiologic response rates (39.3% vs. 44.6%; p = 0.568) were similar in both STK and UK arms. Pain was the most common adverse event in both groups. Significantly more patients in the STK arm developed fever (14% vs. 0%, p = 0.030). Treatment-limiting adverse events occurred in five patients. Conclusions IPFT is a safe and effective method for managing patients with LPEs. Although the clinical and radiologic response rates were similar with STK and UK, the latter may be the preferred choice because of its better safety profile and ease of administration (once-daily dose).

摘要

背景 链激酶(STK)、尿激酶(UK)和阿替普酶进行的胸膜内纤维蛋白溶解疗法(IPFT)仍然是处理局限性胸腔积液(LPE)的常用方法。然而,关于这些药物的比较疗效的数据非常有限。方法 我们比较了66例局限性胸腔积液患者胸膜内注射链激酶(n = 28)和尿激酶(n = 38)的疗效和安全性。如果尽管放置了肋间胸腔引流管或猪尾导管,积液仍未排出,则开始进行IPFT。STK和UK的剂量分别为每日两次250,000 IU和每日一次100,000 IU。比较两组IPFT后引流的液体量、影像学反应、临床反应和不良事件。结果 STK组IPFT后引流的平均液体量为1379 mL,UK组为1110 mL(p = 0.251)。66例患者中,53例(80.3%)有良好的临床反应,28例(43.7%)胸部X线片上积液消退>75%。STK组和UK组的临床反应率(79%对82%;p = 0.765)和影像学反应率(39.3%对44.6%;p = 0.568)相似。疼痛是两组中最常见的不良事件。STK组发热的患者明显更多(14%对0%,p = 0.030)。5例患者出现了限制治疗的不良事件。结论 IPFT是治疗LPE患者的一种安全有效的方法。虽然STK和UK的临床和影像学反应率相似,但由于UK安全性更好且给药方便(每日一次剂量),后者可能是首选。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad67/9308892/c21f54d44bd6/cureus-0014-00000026271-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验